Estie Mermelstein, MSN, FNP-BC

A panel of experts identify real-life barriers to early mycosis fungoides (MF) diagnosis and provide guidance for clinicians evaluating patients with chronic rash.

A link between atopic dermatitis (AD) and incident venous thromboembolism (VTE) is investigated as is the risk for incident VTE in patients with AD who were receiving treatment with JAK inhibitors.

Cemiplimab as neoadjuvant therapy before surgery in adults with resectable cutaneous squamous-cell carcinoma is evaluated.

Efficacy and safety data from the extension phase of a randomized, phase 3 study on apremilast for the treatment of mild to moderate psoriasis is presented.

Researchers sought to identify comorbidities associated with central centrifugal cicatricial alopecia (CCCA).

Associated factors and disease outcomes of adult patients with acute generalized exanthematous pustulosis (AGEP) are identified.

A novel study evaluates the effect of IL-17A blockade, using CJM112, in patients with moderate to severe acne.

The efficacy, safety, and pharmacokinetics of topical cream brepocitinib in adults with mild to moderate atopic dermatitis AD is evaluated.

Side effects after the first and second doses of the BNT162b2 and mRNA-1273 vaccines in patients with and without atopic dermatitis (AD) are assessed.

A study was conducted to determine the diagnostic value of cutaneous manifestations of SARS-CoV-2 infection and the differences between the Delta and Omicron variants.

A study was conducted to determine the efficacy, safety, and impact on quality of life of apremilast therapy in patients with psoriasis.

Researchers conducted a systematic review and meta-analysis to understand the efficacy and safety profile of biologics in children with moderate to severe psoriasis.

The effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis in a real-world setting is assessed.

The risk for the most common autoimmune disorders in patients newly diagnosed with atopic dermatitis (AD) is evaluated.

The safety of upadacitinib in patients with moderate to severe atopic dermatitis (AD) is assessed.

The effect of supplemental enteral glutamine on the time-to-discharge alive in patients with severe burn injuries is assessed.

Are chemotherapeutic agents of value in treating inflammation-induced actinic keratosis?

Researchers put forth safe and efficient monkeypox vaccination possibilities for patients with dermatologic disorders.

The efficacy and safety of fractional lasers vs other conventional treatments as either mono or combined therapy for the treatment of alopecia is assessed.

Researchers report their experience using extracorporeal life support (ECLS) for the treatment of severely burned patients with inhalation injury and acute respiratory distress syndrome (ARDS).

Researchers sought to develop a model to predict the 2-year risk of developing psoriatic arthritis in patients with psoriasis.

The best biologic therapy for individual patients with psoriasis is found using predictive statistical and machine learning models.

The safety and efficacy of up to 2 years tralokinumab treatment in a post hoc interim analysis is reported.

A link between atopic dermatitis and incident venous thromboembolism (VTE) is investigated; the risk for incident VTE in patients with atopic dermatitis who were receiving treatment with JAK inhibitors is also assessed.

The efficacy of topical antifribrinolytic tranexamic acid (TXA) in preventing postoperative bleeding when included in wound care on granulating defects in the setting of Mohs micrographic surgery is assessed.

The genetic spectrum of uncombable hair syndrome (UHS) is clarified.

The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated.

Researchers evaluated the accuracy of machine learning models to predict COVID-19 severity on the basis of patient characteristics and laboratory data.

Does a clinical link exist between diabetes mellitus type 2 and prediabetes and the severity of central centrifugal cicatricial alopecia (CCCA) in Black patients?

The efficacies of systemic treatments with dupilumab, tralokinumab, and Janus kinase inhibitors for moderate to severe atopic dermatitis are compared.